Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users
Section snippets
Background
The primary serologic test for identification of current or past hepatitis C virus (HCV) infection has been the detection of antibody to HCV (anti-HCV). Updated guidelines published by the United States Centers for Disease Control and Prevention (CDC) [1] recommend that serum or plasma found reactive for anti-HCV be followed by nucleic acid testing (NAT) for HCV RNA; a positive HCV RNA result indicates current HCV infection. A viremic person, who is considered currently HCV-infected, should
Objectives
In this study, we evaluated the performance characteristics of the Abbott HCV core antigen assay using evaluation panels that included samples collected from US plasma donors and injecting drug users.
Sample evaluation panels
A total of 551 serum samples previously tested for anti-HCV and HCV RNA formed the two evaluation panels. All samples were stored at −70°C until use. Panel I consisted of 175 plasma samples from a US plasma donor center that were rejected due to anti-HCV-reactivity and/or HCV-RNA-positivity. Panel II consisted of 376 serum samples from a cohort of young injection drug users from California [23] that were positive for anti-HCV and/or HCV RNA. Samples from these two panels were used to evaluate
Results
Panel I: Of 175 plasma donor samples, 73 (41.7%) were anti-HCV-nonreactive/HCV-RNA-positive, 72 (41.1%) were anti-HCV reactive/HCV-RNA-positive, and 30 (17.1%) were anti-HCV-reactive/HCV-RNA-negative (Table 1). Of the anti-HCV and HCV-RNA-positive samples, HCV core antigen was detected in 64 (88.9%) and in all 73 (100%) anti-HCV-nonreactive/HCV-RNA-positive samples. Overall, of the 145 HCV-RNA-positive samples [HCV RNA titers ranged from 2.91 log10 IU/ml to 7.74 log10 IU/mL (mean, 5.69 log10
Discussion
Anti-HCV is the only serological marker for which assays have been approved for clinical use by FDA in the United States. These assays can detect anti-HCV approximately seven weeks after exposure to HCV. However, anti-HCV antibodies are present in an infected person in acute, chronic and resolved phases of infection and therefore cannot distinguish between past and current HCV infection. HCV antigens are detectable in blood of infected individuals within the first two weeks after exposure and
Funding
This work was supported by the Centers for Disease Control and Prevention. Reagents for HCV core antigen testing were supplied by Abbott Diagnostics.
Competing interests
G.J. Dawson and K. Cheng are employed by Abbott Laboratories. All other authors have no commercial or other association that poses a conflict of interest.
Ethical approval
None required.
Acknowledgments
We are grateful to Chris Snead for the use of the Architect i2000SR, Lilia Ganova-Raeva and Tracy Greene-Montfort for genotyping the specimens.
References (39)
- et al.
Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia
J. Hepatol.
(1995) - et al.
A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen
J. Virol. Methods
(2009) - et al.
Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay
J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
(2009) - et al.
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay
J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
(2011) - et al.
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients
J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
(2010) - et al.
Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa
Hepatol. (Baltimore, Md)
(1996) - et al.
New approaches to in vitro diagnosis of hepatitis C infection a reason for post transfusion hepatitis: diagnostic value of determination of hepatitis C virus core antigen
Transf. Apher. Sci.: Off. J. World Apher. Assoc.: Off. J. Eur. Soc. Haemapheresis
(2011) - et al.
Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples
J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
(2013) - et al.
Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA
J. Clin. Virol.
(2012) - et al.
Virus core antigen assay: can we think beyond convention in resource limited settings?
Braz. J. Infect. Dis.: an Off. Publ. Braz. Soc. Infect. Dis.
(2013)
The role of core antigen detection in management of hepatitis C: a critical review
J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol.
Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA
Hepatology (Baltimore, Md)
Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance
J. Hepatol.
Outcomes and treatment of acute hepatitis C virus infection in a United States population
Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc.
Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts
J. Gen. Virol.
Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen
J. Clin. Microbiol.
A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma
J. Med. Virol.
Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of ‘window-phase’ blood donations
Vox sanguinis
Cited by (27)
Genosensors as an alternative diagnostic sensing approaches for specific detection of virus species: A review of common techniques and outcomes
2022, TrAC - Trends in Analytical ChemistryEvaluation of performance characteristics of hepatitis B e antigen serologic assays
2018, Journal of Clinical VirologyCitation Excerpt :We also compared the association of basal core promoter and precore mutations for a subset of samples to assess the sensitivity of the assays in HBeAg mutants. A total of 335 de-identified serum/plasma samples were originally selected for testing [36,37]. These samples were previously tested for HBsAg and HBV DNA, and 253 had adequate volumes for testing with all three evaluated HBeAg assays including 171 serum and plasma donors, 24 pregnant women and 58 individuals from the general US population (Table 1).
Analytical and field evaluation of the Biocentric Generic HCV assay on open polyvalent PCR platforms in France and Cambodia
2018, Journal of Clinical VirologyCitation Excerpt :Although guidelines suggest using ultrasensitive nucleic acid test for HCV (quantification <15 IU/ml), the HCV core antigen test that have an analytical sensitivity equivalent to approximately 500–3000 HCV RNA IU/ml is considered by EASL (European Association for the Study of the Liver) and WHO as a possible alternative to HCV RNA testing [16]. Hence, a lower detection limit ranged between 2 and 3 log10 IU/ml can be considered acceptable regarding HCV RNA concentrations observed in pre-treatment phase [17,18]. Furthermore, the HCV RNA viral load is generally high when virologic failure is diagnosed, 12 weeks or 24 weeks after completion of treatment.
HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia
2018, Enfermedades Infecciosas y Microbiologia ClinicaCitation Excerpt :In our opinion, the utility of this assay is determined by its main advantages: fast turnaround time, cost, and simplicity. Although widespread use of this marker is not foreseeable, we think it could be useful in specific situations such as screening of organ donors,12 low-income settings, or small and low-skilled laboratories with a limited workload. There are also an increasing number of studies proposing the use of HCV-Ag as a first step in the diagnosis of acute and chronic HCV infection.7,13
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
2017, Journal of Clinical Virology